JAC Advance Access originally published online on December 2, 2008
Journal of Antimicrobial Chemotherapy 2009 63(2):340-342; doi:10.1093/jac/dkn494
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original research |
In vitro interactions of micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic phase of Penicillium marneffei
1 Department of Dermatology, Peking University First Hospital, Research Center for Medical Mycology, Peking University, Beijing, P.R. China 2 Department of Dermatology, The First Affiliated Hospital of Guangxi Medical University, Nanning, P.R. China
Received 19 July 2008; returned 2 September 2008; revised 9 November 2008; accepted 11 November 2008
* Corresponding author. Tel: +86-10-66551122, ext. 3056; Fax: +86-10-66551216; E-mail: lrymm{at}medmail.com.cn
Objectives: Penicillium marneffei infection is an important disease among human immunodeficiency virus patients in south-east Asia, including southern China. However, therapeutic strategies are limited. Combination regimens with synergistic drugs could provide additional options for treating penicilliosis. We evaluated the in vitro efficacy of combining micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic yeast form of P. marneffei.
Methods: Twenty isolates of P. marneffei were assayed. Drug interactions were assessed with the chequerboard technique using the CLSI (formerly the NCCLS) microdilution method (M27-A2) with minor modifications. The fractional inhibitory concentration index (FICI) was used to classify drug interactions. Results were interpreted as follows: synergy, FICI 
0.5; no interaction, FICI >0.5 and 4.0; or antagonism, FICI >4.0.
Results: The in vitro interactions of micafungin combined with itraconazole showed the highest percentage of synergic interaction (65%); for the micafungin/amphotericin B combination, 50% of the isolates had synergic interaction. Micafungin significantly enhanced the antifungal activity of amphotericin B and itraconazole against P. marneffei. Micafungin, however, did not enhance the activity of fluconazole and no synergism was observed with this combination. Antagonism was not detected for any of the antifungal combinations assayed.
Conclusions: The results of this study suggest that micafungin enhances the efficacy of itraconazole or amphotericin B in vitro and indicate that an echinocandin, such as micafungin, might have a potential role in combination therapy among patients infected with P. marneffei.
Keywords: dimorphic fungi , antifungal susceptibility , combined therapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. L VandenBussche and D. A Van Loo A Clinical Review of Echinocandins in Pediatric Patients Ann. Pharmacother., January 1, 2010; 44(1): 166 - 177. [Abstract] [Full Text] [PDF]
|
|